This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
A new R&D toolkit called the COVIDome, which has been shared by its developers in the hope that it could accelerate research into new approaches to the clinicalmanagement of COVID-19. What do you get? They have previously used a similar approach to develop TrisomExplorer, a tool used for researching Down syndrome.
Panelists discuss how clinicalmanagement of CAR T-cell therapyassociated toxicities focuses primarily on early recognition and prompt intervention with tocilizumab and/or corticosteroids for cytokine release syndrome (CRS) and immune effector cellassociated neurotoxicity syndrome (ICANS), following established grading systems and treatment algorithms. (..)
Each episode of infection induces a life-long protective immunity to the homologous serotype but confers only partial and transient protection against other serotypes. External Links CDC - Dengue Dengue and Severe Dengue WHO Handbook for ClinicalManagement of Dengue CPG Management of Dengue Infection in Adults, 2015
- Discussing the 4 main drug targets Functional Groups - Quick refresh on IUPAC nomenclature Drug Potency - Refresh on drug potency Drug Metabolism - Discussing Phase I and II reactions, as well as CYP450 system Pharmacogenomics - Discussing some examples Miscellaneous Continuous Professional Development - Needed for renewal of annual retention Immunization (..)
We organize all of the trending information in your field so you don't have to. Join 11,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content